TCW Group Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 169,072 shares of the biopharmaceutical company’s stock after acquiring an additional 12,815 shares during the quarter. TCW Group Inc.’s holdings in Pfizer were worth $6,133,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of PFE. Integrated Investment Consultants LLC grew its stake in shares of Pfizer by 183.9% in the second quarter. Integrated Investment Consultants LLC now owns 117,997 shares of the biopharmaceutical company’s stock valued at $1,587,000 after buying an additional 76,441 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Pfizer by 8.9% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,056,818 shares of the biopharmaceutical company’s stock valued at $38,341,000 after buying an additional 85,928 shares in the last quarter. Cooke & Bieler LP bought a new position in shares of Pfizer in the second quarter valued at $203,000. Mountain Capital Investment Advisors Inc grew its stake in shares of Pfizer by 8.8% in the second quarter. Mountain Capital Investment Advisors Inc now owns 20,221 shares of the biopharmaceutical company’s stock valued at $734,000 after buying an additional 1,628 shares in the last quarter. Finally, Exchange Capital Management Inc. grew its stake in shares of Pfizer by 37.1% in the second quarter. Exchange Capital Management Inc. now owns 33,500 shares of the biopharmaceutical company’s stock valued at $1,215,000 after buying an additional 9,073 shares in the last quarter. 68.95% of the stock is owned by institutional investors.
In other news, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction on Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the sale, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ian C. Read sold 486,753 shares of Pfizer stock in a transaction on Monday, July 16th. The stock was sold at an average price of $37.36, for a total value of $18,185,092.08. Following the sale, the chief executive officer now directly owns 1,145,693 shares of the company’s stock, valued at approximately $42,803,090.48. The disclosure for this sale can be found here. Insiders have sold 761,230 shares of company stock valued at $29,054,690 in the last three months. Insiders own 0.06% of the company’s stock.
PFE stock opened at $43.78 on Friday. Pfizer Inc. has a one year low of $33.20 and a one year high of $45.81. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The firm has a market cap of $262.34 billion, a price-to-earnings ratio of 16.52, a P/E/G ratio of 2.23 and a beta of 0.96.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The company had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. During the same quarter last year, the firm earned $0.67 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.
PFE has been the subject of several analyst reports. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Thursday, October 4th. Morgan Stanley set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, August 29th. Credit Suisse Group lifted their price objective on shares of Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 1st. Bank of America lifted their price objective on shares of Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Finally, JPMorgan Chase & Co. reaffirmed a “$37.66” rating on shares of Pfizer in a research report on Wednesday, July 18th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $42.40.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: Fundamental Analysis
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.